Real-World Phenobarbital Monitoring in Dogs: Serum Concentrations, Hepatic Biochemistry, Lipaemic Failure and Continuity of Care in a University Referral Hospital
Life · 02.11.2026 · 16 (11) · 1858
DOI: 10.3390/life16111858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 02.11.2026. Verfasst von Andreea Despa und 8 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Serum phenobarbital (PB) monitoring is recommended after treatment initiation and periodically thereafter, but real-world data on monitoring practice are scarce, particularly where imepitoin is not marketed and PB is a controlled substance. All in-house PB determinations performed on a point-of-care analyser reporting PB with a hepatic panel at a Romanian university referral hospital between January 2022 and August 2026 were retrieved and linked to the hospital register. A total of 143 canine runs from 66 dogs were obtained; 10 (7.0%) were suppressed by severe lipaemia. At the first valid determination, 47 of 65 dogs with a valid result (72.3%; 95% CI 60.4–81.7) were within the 15–35 µg/mL target range and 16 (24.6%; 95% CI 15.8–36.3) were below it. The median dose, given as fractionated human 100 mg tablets, was 5.62 mg/kg/day and was not associated with concentration; dogs under 10 kg received almost twice the weight-based dose of larger dogs without reaching higher concentrations. Alkaline phosphatase was increased in 36% of runs and was not associated with concentration in mixed-effects models. At least one determination was obtained in 79% of dogs in continued care and 88% of dogs with six or more prescriptions, but only 40% (95% CI 27–56%) of newly treated dogs were determined within 90 days and none of the 17 dogs seen only once or twice after initiation was determined. Monitoring therefore follows continuity of care; scheduling the first determination at initiation and coupling sampling with prescription renewal are proposed measures whose effectiveness requires prospective evaluation.
Zitieren
APA
Despa, A., Anghelinici, D., Bercea-Cazacu, D. N., Stoica, I., Ștefănescu, R. A., Roșca, Ș., Borcea, D. G., Solcan, G., & Musteata, M. (2026). Real-World Phenobarbital Monitoring in Dogs: Serum Concentrations, Hepatic Biochemistry, Lipaemic Failure and Continuity of Care in a University Referral Hospital. Life, 16(11), 1858. https://doi.org/10.3390/life16111858
Vancouver
Despa A, Anghelinici D, Bercea-Cazacu DN, Stoica I, Ștefănescu RA, Roșca Ș, et al. Real-World Phenobarbital Monitoring in Dogs: Serum Concentrations, Hepatic Biochemistry, Lipaemic Failure and Continuity of Care in a University Referral Hospital. Life. 2026;16(11):1858. doi:10.3390/life16111858
BibTeX
@article{Despa2026,
author = {Despa, Andreea and Anghelinici, Dan and Bercea-Cazacu, Dorian Nicolae and Stoica, Iordana and Ștefănescu, Raluca Adriana and Roșca, Ștefania and Borcea, Denis Gabriel and Solcan, Gheorghe and Musteata, Mihai},
title = {Real-World Phenobarbital Monitoring in Dogs: Serum Concentrations, Hepatic Biochemistry, Lipaemic Failure and Continuity of Care in a University Referral Hospital},
journal = {Life},
year = {2026},
volume = {16},
number = {11},
pages = {1858},
doi = {10.3390/life16111858}
}
EUVIMED